During the last decade powerful cardioprotective properties of exogenous recombinant human erythropoietin (rhEPO) have been demonstrated in numerous experimental studies of two different models of myocardial infarction (MI), a permanent coronary ligation and ischemia/reperfusion model, in several species [1]–[6]. Here, EPO is linked to myocardial infarction.